New hope for fertility patients: drug may prevent dangerous ovarian condition
NCT ID NCT07043322
First seen Mar 16, 2026 · Last updated May 09, 2026 · Updated 3 times
Summary
This study tests whether the drug cabergoline can prevent ovarian hyperstimulation syndrome (OHSS), a serious complication of fertility treatments. About 150 women at high risk for OHSS will receive either cabergoline or standard care (coasting). The goal is to see if cabergoline reduces how often OHSS occurs and how severe it is.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GYNECOLOGIC DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mostafa Bahaa
RECRUITINGDamietta, New Damietta, 34518, Egypt
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.